| # | Drug | Count |
|---|---|---|
| 0 | NIRAPARIB | 127 |
| 1 | PEMBROLIZUMAB | 77 |
| 2 | DEXAMETHASONE | 68 |
| 3 | DEXAMETHASONE 1.5 MG | 68 |
| 4 | BEVACIZUMAB | 64 |
| 5 | CARBOPLATIN | 51 |
| 6 | RIBOCICLIB | 50 |
| 7 | LEVETIRACETAM | 41 |
| 8 | PACLITAXEL | 41 |
| 9 | TEMOZOLOMIDE | 33 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | AMCINONIDE | 1 | 0.0123 |
| 1 | NIRAPARIB | 127 | 0.0086 |
| 2 | ENASIDENIB MESYLATE | 15 | 0.0072 |
| 3 | SILTUXIMAB | 2 | 0.0068 |
| 4 | RIBOCICLIB | 50 | 0.0038 |
| 5 | ADO-TRASTUZUMAB EMTANSINE | 16 | 0.0032 |
| 6 | ENFORTUMAB VEDOTIN | 3 | 0.0027 |
| 7 | BRIGATINIB | 5 | 0.0026 |
| 8 | LEVOLEUCOVORIN | 3 | 0.0025 |
| 9 | TEMOZOLOMIDE | 33 | 0.0022 |
| # | Drug class | Count |
|---|---|---|
| 0 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 132 |
| 1 | Corticosteroid [EPC] | 100 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 93 |
| 3 | Kinase Inhibitor [EPC] | 81 |
| 4 | Platinum-based Drug [EPC] | 75 |
| 5 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 65 |
| 6 | Aromatase Inhibitor [EPC] | 60 |
| 7 | Alkylating Drug [EPC] | 58 |
| 8 | Microtubule Inhibitor [EPC] | 53 |
| 9 | Nucleoside Metabolic Inhibitor [EPC] | 42 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-6 Antagonist [EPC] | 2 | 0.0068 |
| 1 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 132 | 0.0054 |
| 2 | Estrogen Receptor Antagonist [EPC] | 25 | 0.0012 |
| 3 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 5 | 0.0011 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 9 | 0.0010 |
| 5 | Aromatase Inhibitor [EPC] | 60 | 0.0007 |
| 6 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 93 | 0.0007 |
| 7 | HER2/neu Receptor Antagonist [EPC] | 29 | 0.0006 |
| 8 | Microtubule Inhibitor [EPC] | 53 | 0.0005 |
| 9 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 65 | 0.0005 |